Cansinobio announced on November 26, 2024, that its application for the expanded age range of the MenHibrix® Meningococcal Polysaccharide Conjugate Vaccine (MCV4) has been accepted by the National Medical Products Administration. This application will expand the applicable population from children aged 3 months to 3 years (47 months) to children aged 3 months to 6 years (83 months). This expansion will further enhance the market coverage of the vaccine. MenHibrix® is the first four-valent meningococcal conjugate vaccine in China, narrowing the gap with developed countries and filling the void in high-end vaccines domestically. The vaccine offers a better preventive solution for infantile meningitis and has demonstrated a unique competitive advantage in the market. Cansinobio continues to promote the market introduction of meningitis vaccines, with sales revenue of...Show More

Cansinobio announced on November 26, 2024, that its application for the expanded age range of the MenHibrix® Meningococcal Polysaccharide Conjugate Vaccine (MCV4) has been accepted by the National Medical Products Administration. This application will expand the applicable population from children aged 3 months to 3 years (47 months) to children aged 3 months to 6 years (83 months). This expansion will further enhance the market coverage of the vaccine. MenHibrix® is the first four-valent meningococcal conjugate vaccine in China, narrowing the gap with developed countries and filling the void in high-end vaccines domestically. The vaccine offers a better preventive solution for infantile meningitis and has demonstrated a unique competitive advantage in the market. Cansinobio continues to promote the market introduction of meningitis vaccines, with sales revenue of meningitis vaccine products reaching 0.516 billion yuan in the first three quarters of 2024, a year-on-year growth of 39.07%. Dr. Xuefeng YU, chairman of Cansinobio, stated that the company will continue to drive the market expansion of meningitis vaccines and is committed to providing high-quality vaccine products. The acceptance of this application for the expanded age range indicates the company's ongoing progress in vaccine research and marketing.